Bicara Therapeutics (BCAX) EBITDA (2023 - 2026)

Bicara Therapeutics' EBITDA history runs 4 years deep, the most recent figure standing at -$60.2 million for Q1 2026.

• On a quarterly basis, EBITDA fell 44.16% year-over-year to -$60.2 million in Q1 2026; TTM through Mar 2026 was -$174.1 million, a 59.98% decrease from a year earlier, with the FY2025 full-year figure at -$155.6 million, down 88.87% from the prior year.
• EBITDA retreated to -$60.2 million in Q1 2026 per BCAX's latest filing, from -$41.1 million in the prior quarter.
• Across five years, EBITDA topped out at -$9.5 million in Q3 2023 and bottomed at -$60.2 million in Q1 2026.
• The 4-year median for EBITDA is -$26.6 million (2024), against an average of -$29.2 million.
• Across the five-year window, EBITDA plunged 171.81% in 2025 and tumbled 44.16% in 2026, its largest moves.
• Year by year, EBITDA stood at -$13.7 million in 2023, then slumped by 94.62% to -$26.6 million in 2024, then plunged by 54.38% to -$41.1 million in 2025, then tumbled by 46.5% to -$60.2 million in 2026.
• Per Business Quant, the three latest BCAX EBITDA figures stand at -$60.2 million (Q1 2026), -$41.1 million (Q4 2025), and -$40.7 million (Q3 2025).